Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dicks Sporting Goods Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Dicks Sporting Goods Inc trades at $202.67 (market cap $18.35B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DKS | |
|---|---|---|
Market Cap | $29.60B | $18.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $239.17 |
52-Week Low | $205.48 | $187.78 |
Enterprise Value | $27.56B | $25.14B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
DKS trades at $203.44, down 4.98% on the day, amid a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with strong profitability metrics including a 20.9% ROE and 4.71% net income margin. Analyst consensus is strongly bullish with a $263.22 price target and no sell ratings. Recent news highlights include positive coverage from Zacks and an upcoming Q2 2026 earnings call on August 25th.
The outlook remains positive given strong fundamentals and analyst support, but risks include competitive pressures and the stock's current bearish technical trend. The key near-term catalyst is the Q2 earnings report, which could validate the bullish sentiment if results meet or exceed the expected EPS of $3.77.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
